塞浦西他啶

塞浦西他啶
臨床資料
读音	(/ˌsaɪproʊˈhɛptədiːn/
商品名（英语：Drug nomenclature）	Periactin, others
AHFS/Drugs.com	Monograph
MedlinePlus	a682541
核准狀況	美 DailyMed: Cyproheptadine;
懷孕分級	澳: A ; ;
给药途径	Oral
ATC碼	R06AX02 (WHO) ;
法律規範狀態
法律規範	澳：限药剂师（S3）; 加：OTC; 英：一般销售列表 (GSL, OTC); 美：处方药（℞-only）; OTC;
藥物動力學數據
血漿蛋白結合率	96 to 99%
药物代谢	Hepatic, mostly CYP3A4 mediated.
生物半衰期	8.6 hours
排泄途徑	糞便 (2–20%; of which, 34% as unchanged drug) 與腎 (40%; none as unchanged drug)
识别信息
	IUPAC命名法 4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine; ;
CAS号	129-03-3 ; 969-33-5（盐酸盐）
PubChem CID	2913;
IUPHAR/BPS	277;
DrugBank	DB00434 ;
ChemSpider	2810 ;
UNII	2YHB6175DO;
KEGG	D07765 ;
ChEBI	CHEBI:4046 ;
ChEMBL	ChEMBL516 ;
CompTox Dashboard（英语：CompTox Chemicals Dashboard） (EPA)	DTXSID8022872 ;
ECHA InfoCard	100.004.482
化学信息
化学式	C21H21N
摩尔质量	287.41 g·mol−1
3D模型（JSmol（英语：JSmol））	交互式图像;
	SMILES c43\C(=C1/CCN(C)CC1)c2ccccc2\C=C/c3cccc4;
	InChI InChI=1S/C21H21N/c1-22-14-12-18(13-15-22)21-19-8-4-2-6-16(19)10-11-17-7-3-5-9-20(17)21/h2-11H,12-15H2,1H3 ; Key:JJCFRYNCJDLXIK-UHFFFAOYSA-N ;

塞浦西他啶（Cyproheptadine），或名賽庚啶 ，是第一代抗組織胺藥，具有抗乙醯膽鹼和局部麻醉的功能，也是兒童抗過敏藥水希普利敏的主要成分。

它於1959年獲得專利，並於1961年用於醫療使用。^[5]

醫療使用

Periactin (cyproheptadine) 4 mg tablets

塞浦西他啶（Cyproheptadine）的3D分子結構表示為空間填充模型

塞浦西他啶用於治療過敏反應 (特別是花粉症).^[6] 用於此目的證實有效，但是第二代抗組織胺藥像是酮替酚與氯雷他定也有相同的結果，且副作用較少。^[7]
它也被用作偏頭痛的預防性治療。在2013年的一項研究中，開始治療後7至10天內，患者的偏頭痛發生率顯著降低。這些患者在服藥前偏頭痛發作的平均頻率為每月8.7次，開始治療後3個月降至每月3.1次。^[7]^[8] 在英國和其他一些國家/地區，藥品仿單上有此用法。
它也被藥品「仿單核准適應症外的使用」在嬰兒週期性嘔吐症候群（英语：cyclical vomiting syndrome）的治療。這種用途的唯一證據來自回顧性研究。^[9]
塞浦西他啶有時被「仿單核准適應症外的使用」，以改善服用抗精神病藥物的患者的静坐不能。^[10]
它也被藥品「仿單核准適應症外的使用」於治療各種皮膚病，包括精神性搔癢症（英语：psychogenic pruritus）|^[11]、藥物誘發的多汗症（出汗過多）^[12]，以及預防表淺性單純性水疱性表皮鬆解症（英语：Epidermolysis bullosa simplex）的水皰形成。^[13]
該藥物的作用之一是食慾增加和體重增加，這導致該藥物在消瘦的兒童以及囊腫性纖維化患者中用於此目的（在美國為「仿單核准適應症外的使用」）。^[14]^[15]^[16]
它也使用在「仿單核准適應症外的使用」治療中度至重度血清素综合症，與使用血清素類（英语：serotonergic）藥物有關的複雜症狀，像是选择性5-羟色胺再摄取抑制剂 (與单胺氧化酶抑制剂)，以及在血清素產生的類癌腫瘤導致血液中5-羥色胺升高的案例。^[17]^[18]

副作用

副作用包括：^[3]^[4]

鎮靜和困倦（通常是短暫的）Sedation and sleepiness (often transient)
頭暈 Dizziness
協調不佳 Disturbed coordination
混亂 Confusion
躁動不安 Restlessness
兴奋 Excitation
緊張 Nervousness
震顫 Tremor
易怒 Irritability
失眠 Insomnia
感覺異常 Paresthesias
神經炎 Neuritis
抽搐 Convulsions
欣快感 Euphoria
幻覺 Hallucinations
歇斯底里 Hysteria
模糊 Faintness
皮疹和水腫的過敏表現 Allergic manifestation of rash and edema
發汗 Diaphoresis
蕁麻疹 Urticaria
對光敏感 Photosensitivity
急性迷路炎 Acute labyrinthitis
複視（雙眼） Diplopia (seeing double)
眩暈 Vertigo
耳鳴 Tinnitus
低血壓 Hypotension (low blood pressure)
心悸 Palpitation
期前收缩 Extrasystoles
過敏性休克 Anaphylactic shock
溶血性貧血 Hemolytic anemia
諸如白细胞减少症，粒細胞缺乏症和血小板減少症等血液異常 Blood dyscrasias such as leukopenia, agranulocytosis and thrombocytopenia
膽汁淤積 Cholestasis
對肝臟的影響：
- 肝炎 Hepatitis
- 黄疸 Jaundice
- 肝功能衰竭 Hepatic failure^[19]
- 肝功能異常 Hepatic function abnormality
上腹窘迫 Epigastric distress
食欲不振 Anorexia
噁心 Nausea
嘔吐 Vomiting
腹瀉 Diarrhea
抗胆碱能副作用:
- 視力模糊 Blurred vision
- 便秘 Constipation
- 口腔乾燥症（口乾） Xerostomia (dry mouth)
- 心動過速（高心率）Tachycardia (high heart rate)
- 尿瀦留 Urinary retention
- 排尿困难 Difficulty passing urine
- 鼻塞 Nasal congestion
- 鼻或喉嚨乾燥 Nasal or throat dryness
頻尿 Urinary frequency
早期月經 Early menses
支氣管分泌物增厚 Thickening of bronchial secretions
胸悶氣喘 Tightness of chest and wheezing
疲勞 Fatigue
寒意 Chills
頭痛 Headache
食慾增加 Increased appetite
體重增加 Weight gain

用藥過量

過量使用時，有時建議使用活性炭進行洗胃。這些症狀通常表明中樞神經系統抑制（或在某些情況下相反地刺激中樞神經系統）和過度的抗膽鹼能副作用。小鼠的半數致死量(LD₅₀)為 123 mg/kg，，大鼠的半數致死量為 295 mg/kg 。^[3]^[4]

藥理

藥效學

塞浦西他啶对此表列出的所有受体均表现为拮抗剂或逆向激动剂。^[20]

塞浦西他啶^[20]
Site	K_i (nM)^[a]	Action^[b]	Species
H₁	0.06	↓	Human
H₂	ND		ND
H₃	>10,000		Human
H₄	202		Human
M₁	12	↓	Human
M₂	7	↓	Human
M₃	12	↓	Human
M₄	8	↓	Human
M₅	11.8	↓	Human
5-HT_1A	59		Human
5-HT_2A	1.67	↓	Human
5-HT_2B	1.54	↓	Human
5-HT_2C	2.23	↓	Human
5-HT₃	228		Mouse
5-HT₆	142		Human
5-HT₇	123		Human
D₁	117		Human
D₂	112	↓	Human
D₃	8		Human
SERT	4,100		Rat
NET	290		Rat
DAT	ND		ND
^ 平衡常数越小，藥物與位點的結合越强。 ^ ↑促效劑 ↓抗拮劑

塞浦西他啶是一种非常有效的抗组胺药或H₁受体的拮抗剂。它在较高浓度下还具有抗胆碱能、抗血清素能和抗多巴胺能活性。它是5-HT₂受体的强效拮抗剂，这是其治疗血清素综合症的基础。

塞浦西他啶具有较弱的的抗雄激素活性。^[21]

藥物代謝動力學

塞浦西他啶口服後吸收良好，血漿濃度峰值出現在1至3小時後。^[22]口服塞浦西他啶的生物半衰期約為8小時。^[2]

化學

塞浦西他啶是三環（英语：Tricyclic）苯並環庚烯（英语：Benzocycloheptene），與吡唑替芬（英语：Pizotifen）和酮替酚以及三環抗抑鬱藥密切相關。

研究

在一項規模較小的精神分裂症患者中，輔助使用塞浦西他啶作為輔助治療，該患者的病情穩定且正在接受其他藥物治療。雖然注意力和口語流利性似乎有所改善，但這項研究規模太小，不足以概括。^[23]在另兩項針對精神分裂症患者的試驗中，也已對其進行了佐劑研究，總共約有50人，並且似乎沒有效果。^[24]

已經進行了一些試驗，以觀察塞浦西他啶是否可以減輕SSRI和抗精神病藥引起的性功能障礙。^[25]

塞浦西他啶已被研究用於創傷後壓力症候群（PTSD）。^[24]

獸醫用途

塞浦西他啶使用在貓的食慾刺激劑（英语：appetite stimulant）^[26] ，也可作為哮喘的輔助治療劑。^[27] 可能的副作用包括刺激和攻擊行為。^[28]它在貓的生物半衰期為 12 小時。^[27]

塞浦西他啶也用在馬的垂體中間部功能障礙（英语：pituitary pars intermedia dysfunction）的二線治療。^[29]^[30]

參考資料

^ Cyproheptadine. Dictionary.com Unabridged. Random House.
^ ^2.0 ^2.1 Gunja N, Collins M, Graudins A. A comparison of the pharmacokinetics of oral and sublingual cyproheptadine. Journal of Toxicology. Clinical Toxicology. 2004, 42 (1): 79–83. PMID 15083941. S2CID 20196551. doi:10.1081/clt-120028749.
^ ^3.0 ^3.1 ^3.2 ^3.3 CYPROHEPTADINE HYDROCHLORIDE tablet [Boscogen, Inc.]. DailyMed. Boscogen, Inc. November 2010 [26 October 2013]. （原始内容 (PDF)存档于2013-07-04）.
^ ^4.0 ^4.1 ^4.2 ^4.3 PRODUCT INFORMATION PERIACTIN® (cyproheptadine hydrochloride) (PDF). Aspen Pharmacare Australia. Aspen Pharmacare Australia Pty Ltd. 17 November 2011 [26 October 2013]. （原始内容 (PDF)存档于29 October 2013）.
^ Fischer, Jnos; Ganellin, C. Robin. Analogue-based Drug Discovery. John Wiley & Sons. 2006: 547 [2020-12-15]. ISBN 9783527607495. （原始内容存档于2021-08-29）（英语）.
^ MedlinePlus Drug Information: Cyproheptadine. [2020-12-15]. （原始内容存档于2008-10-01）.
^ ^7.0 ^7.1 De Bruyne, P; Christiaens, T; Boussery, K; Mehuys, E; Van Winckel, M. Are antihistamines effective in children? A review of the evidence. Archives of Disease in Childhood. January 2017, 102 (1): 56–60. PMID 27335428. S2CID 21185048. doi:10.1136/archdischild-2015-310416.
^ Saito, Y; Yamanaka, G; Shimomura, H; Shiraishi, K; Nakazawa, T; Kato, F; Shimizu-Motohashi, Y; Sasaki, M; Maegaki, Y. Reconsideration of the diagnosis and treatment of childhood migraine: A practical review of clinical experiences. Brain & Development. May 2017, 39 (5): 386–394. PMID 27993427. S2CID 34703034. doi:10.1016/j.braindev.2016.11.011.
^ Salvatore, S; Barberi, S; Borrelli, O; Castellazzi, A; Di Mauro, D; Di Mauro, G; Doria, M; Francavilla, R; Landi, M; Martelli, A; Miniello, VL; Simeone, G; Verduci, E; Verga, C; Zanetti, MA; Staiano, A; SIPPS Working Group on, FGIDs. Pharmacological interventions on early functional gastrointestinal disorders. Italian Journal of Pediatrics. 16 July 2016, 42 (1): 68. PMC 4947301  . PMID 27423188. doi:10.1186/s13052-016-0272-5.
^ Taylor, David; Paton, Carol; Kapur, Shitij. The Maudsley Prescribing Guidelines in Psychiatry. John Wiley & Sons. 2015: 85 [2020-12-15]. ISBN 9781118754573. （原始内容存档于2021-08-28）（英语）.
^ Szepietowski, JC; Reszke, R. Psychogenic Itch Management 50. 2016: 124–32. ISBN 978-3-318-05888-8. PMID 27578081. doi:10.1159/000446055. |journal=被忽略 (帮助)
^ Ashton AK, Weinstein WL. Cyproheptadine for drug-induced sweating. American Journal of Psychiatry. May 2002, 159 (5): 874–5 [2020-12-15]. PMID 11986151. doi:10.1176/appi.ajp.159.5.874-a. （原始内容存档于2012-03-19）.
^ Pfendner, Ellen G.; Bruckner, Anna L. Epidermolysis Bullosa Simplex. GeneReviews. October 13, 2016 [2020-12-15]. PMID 20301543. （原始内容存档于2020-10-22）.
^ Ciproheptadina, estimulante del apetito (Cyproheptadine, appetite stimulant). [2020-12-15]. （原始内容存档于2020-10-24）.
^ Bioplex NF. [2020-12-15]. （原始内容存档于2018-04-18）.
^ Harrison ME, Norris ML, Robinson A, Spettigue W, Morrissey M, Isserlin L. Use of cyproheptadine to stimulate appetite and body weight gain: A systematic review.. Appetite. 2019, 137: 62–72. PMID 30825493. S2CID 72333631. doi:10.1016/j.appet.2019.02.012.
^ Rossi, S (编). Australian Medicines Handbook 2013. Adelaide: The Australian Medicines Handbook Unit Trust. 2013. ISBN 978-0-9805790-9-3.
^ Iqbal, MM; Basil, MJ; Kaplan, J; Iqbal, MT. Overview of serotonin syndrome. Annals of Clinical Psychiatry. November 2012, 24 (4): 310–8. PMID 23145389.
^ Chertoff, Jason. Cyproheptadine-Induced Acute Liver Failure. ACG Case Reports Journal. 8 July 2014, 1 (4): 212–213. PMC 4286888  . PMID 25580444. doi:10.14309/crj.2014.56.
^ ^20.0 ^20.1 Roth, BL; Driscol, J. PDSP K_i Database. Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. [14 August 2017]. （原始内容存档于2021-08-28）.
^ Pucci E, Petraglia F. Treatment of androgen excess in females: yesterday, today and tomorrow. Gynecol. Endocrinol. December 1997, 11 (6): 411–33. PMID 9476091. doi:10.3109/09513599709152569.
^ Lindsay Murray; Frank Daly; David McCoubrie; Mike Cadogan. Toxicology Handbook. Elsevier Australia. 15 January 2011: 388 [27 November 2011]. ISBN 978-0-7295-3939-5. （原始内容存档于2014-01-01）.
^ Buoli, M; Altamura, AC. May non-antipsychotic drugs improve cognition of schizophrenia patients?. Pharmacopsychiatry. March 2015, 48 (2): 41–50. PMID 25584772. doi:10.1055/s-0034-1396801.
^ ^24.0 ^24.1 Dabaghzadeh, F; Khalili, H; Ghaeli, P; Dashti-Khavidaki, S. Potential benefits of cyproheptadine in HIV-positive patients under treatment with antiretroviral drugs including efavirenz. Expert Opinion on Pharmacotherapy. December 2012, 13 (18): 2613–24. PMID 23140169. S2CID 25769557. doi:10.1517/14656566.2012.742887.
^ Nunes, LV; Moreira, HC; Razzouk, D; Nunes, SO; Mari Jde, J. Strategies for the treatment of antipsychotic-induced sexual dysfunction and/or hyperprolactinemia among patients of the schizophrenia spectrum: a review. Journal of Sex & Marital Therapy. 2012, 38 (3): 281–301. PMID 22533871. S2CID 23406005. doi:10.1080/0092623X.2011.606883.
^ Agnew, W; Korman, R. Pharmacological appetite stimulation: rational choices in the inappetent cat. Journal of Feline Medicine and Surgery. September 2014, 16 (9): 749–56. PMID 25146662. S2CID 37126352. doi:10.1177/1098612X14545273.
^ ^27.0 ^27.1 Dowling PM. Systemic Therapy of Airway Disease: Cyproheptadine. Kahn CM, Line S, Aiello SE (编). The Merck Veterinary Manual 9th. John Wiley & Sons. February 8, 2005 [2022-06-16]. ISBN 978-0-911910-50-6. （原始内容存档于2016-03-04）. Retrieved on October 26, 2008.
^ Dowling PM. Drugs Affecting Appetite. Kahn CM, Line S, Aiello SE (编). The Merck Veterinary Manual 9th. John Wiley & Sons. February 8, 2005 [2022-06-16]. ISBN 978-0-911910-50-6. （原始内容存档于2012-10-28）. Retrieved on October 26, 2008.
^ Durham, AE. Therapeutics for Equine Endocrine Disorders. The Veterinary Clinics of North America. Equine Practice. April 2017, 33 (1): 127–139. PMID 28190613. doi:10.1016/j.cveq.2016.11.003.
^ Merck Vet Manual. Hirsutism Associated with Adenomas of the Pars Intermedia. [April 24, 2011]. （原始内容存档于2016-03-03）.

#invoke:navbox

[21] 平衡常数越小，藥物與位點的結合越强。

[22] 
↑促效劑
↓抗拮劑

[3] 促效劑

[4] ↓抗拮劑

[1] Cyproheptadine. Dictionary.com Unabridged. Random House.

[pmid15083941-2] 2.0 ^2.1 Gunja N, Collins M, Graudins A. A comparison of the pharmacokinetics of oral and sublingual cyproheptadine. Journal of Toxicology. Clinical Toxicology. 2004, 42 (1): 79–83. PMID 15083941. S2CID 20196551. doi:10.1081/clt-120028749.

[DM-3] 3.0 ^3.1 ^3.2 ^3.3 CYPROHEPTADINE HYDROCHLORIDE tablet [Boscogen, Inc.]. DailyMed. Boscogen, Inc. November 2010 [26 October 2013]. （原始内容 (PDF)存档于2013-07-04）.

[TGA-4] 4.0 ^4.1 ^4.2 ^4.3 PRODUCT INFORMATION PERIACTIN® (cyproheptadine hydrochloride) (PDF). Aspen Pharmacare Australia. Aspen Pharmacare Australia Pty Ltd. 17 November 2011 [26 October 2013]. （原始内容 (PDF)存档于29 October 2013）.

[Fis2006-5] Fischer, Jnos; Ganellin, C. Robin. Analogue-based Drug Discovery. John Wiley & Sons. 2006: 547 [2020-12-15]. ISBN 9783527607495. （原始内容存档于2021-08-29）（英语）.

[6] MedlinePlus Drug Information: Cyproheptadine. [2020-12-15]. （原始内容存档于2008-10-01）.

[DeBruyne2017-7] 7.0 ^7.1 De Bruyne, P; Christiaens, T; Boussery, K; Mehuys, E; Van Winckel, M. Are antihistamines effective in children? A review of the evidence. Archives of Disease in Childhood. January 2017, 102 (1): 56–60. PMID 27335428. S2CID 21185048. doi:10.1136/archdischild-2015-310416.

[8] Saito, Y; Yamanaka, G; Shimomura, H; Shiraishi, K; Nakazawa, T; Kato, F; Shimizu-Motohashi, Y; Sasaki, M; Maegaki, Y. Reconsideration of the diagnosis and treatment of childhood migraine: A practical review of clinical experiences. Brain & Development. May 2017, 39 (5): 386–394. PMID 27993427. S2CID 34703034. doi:10.1016/j.braindev.2016.11.011.

[9] Salvatore, S; Barberi, S; Borrelli, O; Castellazzi, A; Di Mauro, D; Di Mauro, G; Doria, M; Francavilla, R; Landi, M; Martelli, A; Miniello, VL; Simeone, G; Verduci, E; Verga, C; Zanetti, MA; Staiano, A; SIPPS Working Group on, FGIDs. Pharmacological interventions on early functional gastrointestinal disorders. Italian Journal of Pediatrics. 16 July 2016, 42 (1): 68. PMC 4947301  . PMID 27423188. doi:10.1186/s13052-016-0272-5.

[Maudsley-10] Taylor, David; Paton, Carol; Kapur, Shitij. The Maudsley Prescribing Guidelines in Psychiatry. John Wiley & Sons. 2015: 85 [2020-12-15]. ISBN 9781118754573. （原始内容存档于2021-08-28）（英语）.

[11] Szepietowski, JC; Reszke, R. Psychogenic Itch Management 50. 2016: 124–32. ISBN 978-3-318-05888-8. PMID 27578081. doi:10.1159/000446055. |journal=被忽略 (帮助)

[12] Ashton AK, Weinstein WL. Cyproheptadine for drug-induced sweating. American Journal of Psychiatry. May 2002, 159 (5): 874–5 [2020-12-15]. PMID 11986151. doi:10.1176/appi.ajp.159.5.874-a. （原始内容存档于2012-03-19）.

[13] Pfendner, Ellen G.; Bruckner, Anna L. Epidermolysis Bullosa Simplex. GeneReviews. October 13, 2016 [2020-12-15]. PMID 20301543. （原始内容存档于2020-10-22）.

[14] Ciproheptadina, estimulante del apetito (Cyproheptadine, appetite stimulant). [2020-12-15]. （原始内容存档于2020-10-24）.

[15] Bioplex NF. [2020-12-15]. （原始内容存档于2018-04-18）.

[cyapp-16] Harrison ME, Norris ML, Robinson A, Spettigue W, Morrissey M, Isserlin L. Use of cyproheptadine to stimulate appetite and body weight gain: A systematic review.. Appetite. 2019, 137: 62–72. PMID 30825493. S2CID 72333631. doi:10.1016/j.appet.2019.02.012.

[AMH-17] Rossi, S (编). Australian Medicines Handbook 2013. Adelaide: The Australian Medicines Handbook Unit Trust. 2013. ISBN 978-0-9805790-9-3.

[18] Iqbal, MM; Basil, MJ; Kaplan, J; Iqbal, MT. Overview of serotonin syndrome. Annals of Clinical Psychiatry. November 2012, 24 (4): 310–8. PMID 23145389.

[19] Chertoff, Jason. Cyproheptadine-Induced Acute Liver Failure. ACG Case Reports Journal. 8 July 2014, 1 (4): 212–213. PMC 4286888  . PMID 25580444. doi:10.14309/crj.2014.56.

[PDSP-20] 20.0 ^20.1 Roth, BL; Driscol, J. PDSP K_i Database. Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. [14 August 2017]. （原始内容存档于2021-08-28）.

[pmid9476091-23] Pucci E, Petraglia F. Treatment of androgen excess in females: yesterday, today and tomorrow. Gynecol. Endocrinol. December 1997, 11 (6): 411–33. PMID 9476091. doi:10.3109/09513599709152569.

[MurrayDaly2011-24] Lindsay Murray; Frank Daly; David McCoubrie; Mike Cadogan. Toxicology Handbook. Elsevier Australia. 15 January 2011: 388 [27 November 2011]. ISBN 978-0-7295-3939-5. （原始内容存档于2014-01-01）.

[25] Buoli, M; Altamura, AC. May non-antipsychotic drugs improve cognition of schizophrenia patients?. Pharmacopsychiatry. March 2015, 48 (2): 41–50. PMID 25584772. doi:10.1055/s-0034-1396801.

[Dabaghzadeh2012-26] 24.0 ^24.1 Dabaghzadeh, F; Khalili, H; Ghaeli, P; Dashti-Khavidaki, S. Potential benefits of cyproheptadine in HIV-positive patients under treatment with antiretroviral drugs including efavirenz. Expert Opinion on Pharmacotherapy. December 2012, 13 (18): 2613–24. PMID 23140169. S2CID 25769557. doi:10.1517/14656566.2012.742887.

[27] Nunes, LV; Moreira, HC; Razzouk, D; Nunes, SO; Mari Jde, J. Strategies for the treatment of antipsychotic-induced sexual dysfunction and/or hyperprolactinemia among patients of the schizophrenia spectrum: a review. Journal of Sex & Marital Therapy. 2012, 38 (3): 281–301. PMID 22533871. S2CID 23406005. doi:10.1080/0092623X.2011.606883.

[28] Agnew, W; Korman, R. Pharmacological appetite stimulation: rational choices in the inappetent cat. Journal of Feline Medicine and Surgery. September 2014, 16 (9): 749–56. PMID 25146662. S2CID 37126352. doi:10.1177/1098612X14545273.

[MVM2-29] 27.0 ^27.1 Dowling PM. Systemic Therapy of Airway Disease: Cyproheptadine. Kahn CM, Line S, Aiello SE (编). The Merck Veterinary Manual 9th. John Wiley & Sons. February 8, 2005 [2022-06-16]. ISBN 978-0-911910-50-6. （原始内容存档于2016-03-04）. Retrieved on October 26, 2008.

[MVM1-30] Dowling PM. Drugs Affecting Appetite. Kahn CM, Line S, Aiello SE (编). The Merck Veterinary Manual 9th. John Wiley & Sons. February 8, 2005 [2022-06-16]. ISBN 978-0-911910-50-6. （原始内容存档于2012-10-28）. Retrieved on October 26, 2008.

[31] Durham, AE. Therapeutics for Equine Endocrine Disorders. The Veterinary Clinics of North America. Equine Practice. April 2017, 33 (1): 127–139. PMID 28190613. doi:10.1016/j.cveq.2016.11.003.

[32] Merck Vet Manual. Hirsutism Associated with Adenomas of the Pars Intermedia. [April 24, 2011]. （原始内容存档于2016-03-03）.

[1]

[3]

[4]

[2]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]

[15]

[16]

[17]

[18]

[19]

[20]

[a]

[b]

[21]

[22]

[23]

[24]

[25]

[26]

[27]

[28]

[29]

[30]

臨床資料


读音	(/ˌsaɪproʊˈhɛptədiːn/^[1]
商品名（英语：Drug nomenclature）	Periactin, others
AHFS/Drugs.com	Monograph
MedlinePlus	a682541
核准狀況	美 DailyMed: Cyproheptadine
懷孕分級	澳: A
给药途径	Oral
ATC碼	R06AX02 (WHO)
法律規範狀態
法律規範	澳：限药剂师（S3）加：OTC 英：一般销售列表 (GSL, OTC) 美：处方药（℞-only） OTC
藥物動力學數據
血漿蛋白結合率	96 to 99%
药物代谢	Hepatic,^[3]^[4] mostly CYP3A4 mediated.
生物半衰期	8.6 hours^[2]
排泄途徑	糞便 (2–20%; of which, 34% as unchanged drug) 與腎 (40%; none as unchanged drug)^[3]^[4]
识别信息
IUPAC命名法 4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine
CAS号	129-03-3 ^Y 969-33-5（盐酸盐）
PubChem CID	2913
IUPHAR/BPS	277
DrugBank	DB00434^Y
ChemSpider	2810^Y
UNII	2YHB6175DO
KEGG	D07765^Y
ChEBI	CHEBI:4046^Y
ChEMBL	ChEMBL516^Y
CompTox Dashboard（英语：CompTox Chemicals Dashboard） (EPA)	DTXSID8022872
ECHA InfoCard	100.004.482
化学信息
化学式	C₂₁H₂₁N
摩尔质量	287.41 g·mol⁻¹
3D模型（JSmol（英语：JSmol））	交互式图像
SMILES c43\C(=C1/CCN(C)CC1)c2ccccc2\C=C/c3cccc4
InChI InChI=1S/C21H21N/c1-22-14-12-18(13-15-22)21-19-8-4-2-6-16(19)10-11-17-7-3-5-9-20(17)21/h2-11H,12-15H2,1H3^Y Key:JJCFRYNCJDLXIK-UHFFFAOYSA-N^Y